On September 21, 2019 Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, reported that results from a clinical phase I study of the drug candidate ADC-1013 (JNJ-64457107) will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 32nd Annual Meeting, held from 8-12 November 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland, US (Press release, Alligator Bioscience, SEP 21, 2017, View Source [SID1234538685]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alligator Bioscience will give both an oral and poster presentation at the SITC (Free SITC Whitepaper) conference with the title: "First-in-human study with intratumoral administration of a CD40 agonistic antibody: preliminary results with ADC-1013/JNJ-64457107 in advanced solid malignancies". The oral presentation will be held at Session Clinical Trials: New Agents, starting at 1:45 p.m. ET (7:45 p.m. CET) on November 10, 2017.

For further information about the program, please visit the conference web site:
View Source

For further information:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 286 44 95
E-mail: [email protected].

This release contains information that Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CEST on 21 September 2017.

Notes to editors

About ADC-1013

ADC-1013 is a drug candidate intended for immunotherapy of different types of cancer. Pre-clinical data have shown that the ADC-1013 antibody effectively activates T-cells, mediated through binding to the co-stimulatory receptor CD40 on dendritic cells. The increased T cell activation enables the immune system to attack the cancer. In addition, since some cancer cells express CD40 on the surface, ADC-1013 may act also through a secondary mechanism of action killing cancer cells directly.

In August 2015, Alligator licensed global development rights for ADC-1013 to Janssen Biotech Inc. In October 2016, Janssen Biotech, Inc. started a second phase I clinical study (ClinicalTrials: NCT02829099). That study is an intravenous dose escalation study with ADC-1013 (JNJ-64457107).

About the ADC-1013 clinical Phase I study

The study to be presented is a multicenter, open-label phase I study in patients with advanced solid tumors evaluating safety and tolerability, pharmacokinetics, immunogenicity, biomarker response and clinical response. The study is a dose-escalation study involving intratumoral and intravenous administration of ADC-1013 at five hospitals in Sweden, Denmark and the UK. The study was performed by Alligator and includes 24 patients and ten different tumor types. For further information, please visit View Source; NCT02379741.

On September 21, 2017 Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, reported that the pricing of its follow-on public offering of 6,100,000 shares of its common stock at a price to the public of $41.00 per share (Press release, Juno, SEP 21, 2017, View Source;p=RssLanding&cat=news&id=2302262 [SID1234520595]). In addition, Juno has granted the underwriters a 30-day option to purchase up to an additional 915,000 shares of common stock. Juno intends to use the net proceeds of the offering for general corporate purposes and working capital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offering is expected to close on September 26, 2017, subject to customary closing conditions. Concurrent with the completion of the follow-on public offering, Juno will complete a private placement of 659,415 shares of its common stock, at a price of $41.00 per share, to a subsidiary of Celgene Corporation. Aggregate gross proceeds from the follow-on public offering and concurrent private placement, before deducting underwriting discounts and commissions, in the case of the follow-on public offering, and expenses payable by Juno will be $277.1 million (or approximately $318.7 million if the underwriters exercise their option to purchase additional shares in full).
Morgan Stanley and J.P. Morgan are acting as joint book-running managers for the offering. Barclays and Leerink Partners are acting as co-lead managers and Wells Fargo Securities, Raymond James and Wedbush PacGrow are acting as co-managers.

A registration statement on Form S-3 relating to the common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on September 20, 2017 and was automatically effective upon filing. The offering is being made only by means of a written prospectus that forms a part of the registration statement. Copies of the final prospectus related to the offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, or by telephone at (866) 803-9204.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On September 20, 2017 Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") and SymBio Pharmaceuticals Limited ("SymBio") (Tokyo Stock Exchange/JASDAQ 4582) reported that the Company has licensed to SymBio rights under Eagle’s intellectual property to develop, market and sell Eagle’s bendamustine hydrochloride ("bendamustine HCl") ready-to-dilute ("RTD") and rapid infusion ("RI") injection products in Japan (Press release, Eagle Pharmaceuticals, SEP 20, 2017, View Source [SID1234540126]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SymBio will be responsible for securing regulatory approval of the RTD and RI injection products using the licensed technology in Japan with a target for approval of a product in 2020. SymBio currently markets TREAKISYM in Japan, a lyophilized powder formulation of bendamustine HCl indicated for chronic lymphocytic leukemia ("CLL"); relapsed or refractory low-grade Hodgkin’s lymphoma ("NHL"); mantle cell lymphoma ("MCL"); and as a first line treatment of low-grade NHL and MCL. According to SymBio, 12-month sales ended June 30, 2017 in Japan for TREAKISYM were $52 million, due to the approval of first line treatment for NHL and MCL in December 2016. SymBio has estimated that sales of TREAKISYM are estimated to grow to $90 million in 2018.

A 50 ml RI or rapid infusion presentation of bendamustine hydrochloride injection is currently marketed in the U.S. by Teva Pharmaceutical Industries, Ltd. ("Teva") as BENDEKA (bendamustine HCl) Injection. BENDEKA currently has a 97% market share of the bendamustine market, and Teva has forecasted the North American market for bendamustine to be approximately $600 – $660 million in sales in 2017. BENDEKA’s low volume infusion and short infusion time represents an important benefit to both patients and healthcare providers.

Pursuant to the terms of the license with SymBio, Eagle will receive a $12.5 million upfront milestone payment, and may be entitled to additional milestone payments upon approval and the achievement of cumulative sales thresholds. The Company will also receive royalties on future net sales of the licensed bendamustine products.

"This is an important example of the value of the Eagle portfolio to patients worldwide and a first step in expanding outside the U.S. for our differentiated products. We look forward to SymBio’s future approval and successful commercialization of bendamustine HCI in Japan," stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.

Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio, stated, "In-licensing Eagle’s ready-to-dilute and rapid infusion injection products will enable SymBio to extend the product life and continue to maximize the value of TREAKISYM over the product life while bringing significant benefits to patients and healthcare providers in Japan."

On September 19, 2017 Petra Pharma, a drug development company focused on novel enzyme targets, and Schrödinger, Inc., a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods, reported a multi-target research collaboration to develop novel therapeutics for the treatment of cancer and metabolic diseases (Press release, Schrodinger, SEP 19, 2017, View Source [SID1234525274]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, the companies will work together to leverage Petra’s pipeline of unique enzyme targets and Schrödinger’s computational drug discovery platform in the design of novel small molecules for the treatment of cancer and metabolic diseases. Schrödinger will receive preclinical, clinical and commercial-stage milestone payments, as well as equity in Petra. Additional details and financial terms of the collaboration were not disclosed.

"Collaborating with Schrödinger gives us access to cutting-edge computational tools for drug design," said Brian O’Callaghan, President and Chief Executive Officer at Petra Pharma. "Combined with our expertise in novel enzyme targets, we look forward to leveraging this partnership to design and develop new treatment options for people with limited treatment options who suffer from cancer and metabolic diseases."

"We are looking forward to working with Petra’s highly talented team to accelerate the discovery of novel therapies." said Ramy Farid, Schrödinger’s President and CEO. "This partnership highlights the versatility of our computational drug discovery platform, which will support and enable Petra’s efforts to design innovative new drugs that may have an important impact on the lives of patients."

Petra Pharma is backed by a group of investors including AbbVie, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, 180 Degree Capital Corp., Empire State Development’s Innovate NY Fund, Johnson & Johnson Innovation – JJDC, Inc., Partnership Fund for New York City, Pfizer Venture Investments, Watson Fund and WuXi PharmaTech.

On September 19, 2017 Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN, a first-in-class, intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, reported that it will present at the Phacilitate Immuno-Oncology Frontiers Conference (Press release, Oncolytics Biotech, SEP 19, 2017, View Source [SID1234520576]). Dr. Andres Gutierrez, Oncolytics’ Chief Medical Officer, will present at 4:00 pm CEST on September 21, 2017 at the Maritim Proarte Hotel. The conference takes place on September 20th and 21st in Berlin, Germany.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Know more, wherever you are:
Latest on Oncolytics Biotech’s Cancer Pipeline, book your free 1stOncology demo here.

Dr. Gutierrez will highlight the role of REOLYSIN in the activation of the immune system and the induction of an inflamed tumor phenotype in the tumor microenvironment. His presentation will also review certain historical clinical programs, highlight the positive survival data from the IND 213 study in metastatic breast cancer (mBC) and the pooled safety database – the largest of any oncolytic virus.

"We want to share our extensive experience with REOLYSIN in the clinic to illustrate the specific expertise and efforts required to develop an oncolytic virus for intravenous administration and systemic exposure in oncology," said Dr. Gutierrez. "This experience helped us define a clear regulatory pathway for registration in metastatic breast cancer. With an overall agreement with the FDA on the phase 3 study design, details of the pivotal registration study will be made available following evaluation and completion of discussions with clinical advisors and potentially partners, as well as European regulators."

The Phacilitate Immuno-Oncology Frontiers conference hosts over 300 industry decision-makers and key external stakeholders to come together discuss and define a strategic roadmap to success for immuno-oncology developers, ensuring European patients gain access to the game-changing biotherapeutics of tomorrow. Immuno-Oncology frontiers Berlin is the only European event that offers extensive coverage of the latest emerging science whilst placing it in its wider strategic context as the basis of tomorrow’s successful business and commercialisation models.

About REOLYSIN
REOLYSIN is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers.